16,303 Shares in Enliven Therapeutics, Inc. $ELVN Purchased by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL acquired a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 16,303 shares of the company’s stock, valued at approximately $334,000.

Several other institutional investors have also added to or reduced their stakes in ELVN. BNP Paribas Financial Markets increased its stake in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares in the last quarter. Quantbot Technologies LP lifted its stake in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at approximately $96,000. Tower Research Capital LLC TRC boosted its holdings in Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after buying an additional 3,490 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new position in Enliven Therapeutics in the 3rd quarter valued at approximately $211,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $37.79 on Thursday. The firm has a fifty day moving average price of $29.22 and a two-hundred day moving average price of $23.37. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -20.32 and a beta of 0.33. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $40.62.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ELVN has been the topic of a number of analyst reports. Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Mizuho lifted their price target on Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, March 25th. HC Wainwright increased their price objective on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $43.40.

Insiders Place Their Bets

In other news, insider Joseph P. Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $29.04, for a total transaction of $145,200.00. Following the completion of the sale, the insider owned 740,188 shares in the company, valued at approximately $21,495,059.52. This trade represents a 0.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Benjamin Hohl sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the transaction, the chief financial officer owned 51,000 shares in the company, valued at approximately $1,508,580. This trade represents a 16.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 232,180 shares of company stock worth $6,217,033. 25.90% of the stock is currently owned by insiders.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.